Wilfried Roeloffzen
A5011050853- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Dermatological and Skeletal Disorders
- Peptidase Inhibition and Analysis
- Cancer therapeutics and mechanisms
- Synthesis and Biological Evaluation
- Insect Resistance and Genetics
- HIV/AIDS drug development and treatment
- Genetic factors in colorectal cancer
- Quinazolinone synthesis and applications
- Ubiquitin and proteasome pathways
- Research on Leishmaniasis Studies
- Sarcoidosis and Beryllium Toxicity Research
- Blood transfusion and management
- Platelet Disorders and Treatments
- Pancreatitis Pathology and Treatment
- Blood properties and coagulation
- Neuroendocrine Tumor Research Advances
- Radiation Dose and Imaging
University Medical Center Groningen
2010-2024
University of Groningen
2010-2024
Treant Zorggroep
2017-2018
Ziekenhuis Groep Twente
1998
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils light chains produced clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. We randomly assigned patients with newly diagnosed AL to receive six cycles bortezomib, cyclophosphamide, and dexamethasone either alone (control group) or subcutaneous daratumumab followed single-agent every 4 weeks up 24 (daratumumab group). The primary end...
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel earlier treatment lines lenalidomide-refractory disease. Download PDF of the Research Summary. In this phase 3, randomized, open-label trial, we assigned myeloma to receive physician's choice standard care. All had received one three previous treatment. The primary outcome was...
Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined bortezomib, lenalidomide, and dexamethasone (VRd) the treatment transplantation-eligible patients newly diagnosed multiple is needed. Download PDF Research Summary. In this phase 3 trial, we randomly assigned 709 to receive either VRd induction consolidation therapy lenalidomide maintenance (D-VRd group) or alone (VRd group). The...
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life care (SOC) in triple-class exposed (received at least a PI, IMiD, mAb) relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status 0-1, ≥3 prior lines...
Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in new treatments recent years, yet real-world data on the management of disease are scarce. EMN23 retrospective, observational study patients who initiated first-line treatment 2004-2018 Europe, presenting demographics, clinical characteristics, patterns, outcomes, from 4480 patients. Regimens based bortezomib were most frequently used as therapy; only 6.2% received autologous stem cell...
Our objective was to analyze the effects of age, gender, and use oral contraceptives (OCs) on coagulation using thrombelastography (TEG), a single test both plasma factors cellular elements in whole blood.TEG variables were measured native blood recalcified citrated from 120 healthy adults (60 men 60 women) with various ages an additional 29 women OCs.We observed hypercoagulability compared OCs age-matched nonusers. Moreover, we found aging. Using method Bland Altman (Lancet 1986;1:307-10),...
Background: The increasing sub-classification of cancer patients due to more detailed molecular classification tumors, and limitations current trial designs, require innovative research designs. We present the design, governance standing three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, colorectal (NCT02070146). Multidisciplinary collection clinical data, tumor tissue, blood samples, patient-reported outcome (PRO) measures with a coverage, provides...
To study serum neurofilament light chain (sNfL) in amyloid (AL) amyloidosis patients with and without polyneuropathy (PNP) to corroborate previous observations that sNfL is increased hereditary transthyretin-related (ATTRv) PNP.sNfL levels were assessed retrospectively AL PNP (AL/PNP+ AL/PNP-, respectively), ATTRv (ATTRv/PNP+), asymptomatic transthyretin (TTR) gene mutation carriers (TTRv carriers) healthy controls. Healthy controls (HC) age- sex-matched both AL/PNP- (HC/AL) TTRv (HC/TTRv)....
8029 Background: In cohort B of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study, efficacy and safety cilta-cel are being evaluated in patients (pts) with MM who had early relapse after initial therapy. These pts have functionally high-risk disease, post autologous stem cell transplantation (ASCT) a poor prognostic factor representing an unmet medical need. We present updated results. Methods: Eligible MM, received 1 prior LOT (PI IMiD required), disease progression per IMWG (either...
7505 Background: CARTITUDE-2 is a phase 2 multicohort study evaluating ciltacabtagene autoleucel (cilta-cel) across various clinical settings. Cohort D cilta-cel ± lenalidomide (len) maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM) who achieved less than complete response (CR) after autologous stem cell transplant (ASCT) frontline therapy (tx). We report efficacy and safety for this cohort. Methods: Adults NDMM per IMWG criteria, best of <CR ≥stable disease 4–8...
Currently there is no sensitive laboratory test to establish the influence of red blood cells (RBCs) on hemostasis. As thromboelastography (TEG) measures hemostasis in whole blood, taking into account interactions all cellular elements, we used this instrument investigate role that RBCs play hemostasis.In 29 patients with chemotherapy-induced anemia studied effect progressive coagulation profile. In 24 chronic transfusion coagulation. Finally, 18 evaluated whether storage time has additional...
Thrombelastography (TEG) is used as a point-of-care test of hemostasis. Different components the tracing are considered to reflect various parts hemostatic system and distinguish low platelet count, dysfunction or both from lack plasmatic coagulation factors. To analyze influence one single element system, namely we TEG serially in patients with well documented transient thrombocytopenia. A total 189 analyses were performed 16 hematological malignancy remission, receiving consolidation...